Welcome to our dedicated page for Inogen news (Ticker: INGN), a resource for investors and traders seeking the latest updates and insights on Inogen stock.
Inogen Inc. (INGN) is a pioneering medical technology company committed to enhancing the quality of life for supplemental oxygen users. Founded in 2001, Inogen emerged from a personal story of necessity and innovation. The company's mission began when Mae, the grandmother of one of the founders, was prescribed oxygen therapy, highlighting the need for more user-friendly and portable oxygen solutions. You can learn more about Mae's story here.
Inogen aims to revolutionize oxygen therapy technology, striving to keep pace with the active lifestyles of patients who rely on oxygen to lead fulfilling lives. The company estimates that over 2.5 million patients in the United States and more than 4.5 million patients worldwide use oxygen therapy.
The company's flagship product, the Inogen One system, is a compact, lightweight, and travel-approved portable oxygen concentrator designed to liberate patients from the constraints of heavy tanks, frequent refills, and stationary systems. This innovation provides patients with the freedom and independence to live their lives by moments, not by the minutes left in an oxygen tank.
Inogen's products and services are sold through various channels, including home medical equipment providers, distributors, large gas companies, and home oxygen providers. The company also rents its products directly to patients, generating the majority of its revenue within the United States.
Inogen's commitment to continuous improvement is evident in its ongoing projects and recent achievements. The company constantly works toward refining its product offerings and expanding its reach to benefit more patients globally.
Inogen, Inc. reported Q1 2022 total revenue of $80.4 million, down 7.5% year-over-year due to supply chain issues. However, revenue increased 5.2% sequentially from Q4 2021. Domestic direct-to-consumer sales rose 12.2% to $34.4 million, while business-to-business sales dropped 83.4% to $5.1 million. International business-to-business revenue surged 77.7% to $27.9 million. A net loss of $14.2 million was reported, with adjusted loss per diluted share of $0.39. The company did not provide revenue guidance for 2022, citing ongoing market uncertainties.
Sommetrics, focused on enhancing sleep health, reported key Q1 2022 achievements, notably advancing clinical activities for FDA clearance of aerSleep® II, a non-invasive treatment for obstructive sleep apnea. The six-month SUPRA pivotal trial is ongoing at various U.S. sleep centers, with promising safety data. Recent patent approvals in the U.S. and Japan bolster its intellectual property, totaling 36 patents. The company is targeting $16 million in its Series C financing, raising $11 million so far. Scott Wilkinson, former Inogen CEO, has been appointed as Advisor to guide aerSleep® II's market entry.
Inogen, Inc (NASDAQ: INGN) announced its first quarter 2022 financial results will be released after market close on
Inogen, a medical technology company specializing in homecare respiratory products, announced its participation in the 21st Annual Needham Virtual Healthcare Conference. CEO Nabil Shabshab and CFO Kristin Caltrider are set to present on April 13, 2021, at 12:45 p.m. ET. Interested parties can access the live webcast on Inogen's Investor Relations page. The presentation will be available for replay for 90 days following the event. Inogen is known for developing portable oxygen concentrators aimed at patients with chronic respiratory conditions.
Inogen, Inc. (NASDAQ: INGN) announced participation in the KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2022, at 4:30 p.m. ET. The company's President and CEO, Nabil Shabshab, and CFO, Kristin Caltrider, will present at the event. A webcast will be available on the Inogen Investor Relations website, with a replay accessible for 90 days post-presentation. Inogen specializes in developing and marketing portable oxygen concentrators for chronic respiratory conditions, aiming to enhance homecare solutions for patients.
Inogen, Inc. (NASDAQ: INGN) appointed Kristin Caltrider as EVP & Chief Financial Officer, effective March 21, 2022, succeeding interim CFO Mike Sergesketter. Nabil Shabshab, CEO, expressed confidence in Caltrider's proven experience in healthcare financial operations. Caltrider previously served as Vice President of Finance at Quidel Corporation. She aims to leverage Inogen's strong talent base and strategic plan for sustainable growth. The transition aims for smooth continuity as the company seeks to enhance its position in the respiratory care MedTech sector.
Inogen, Inc. (NASDAQ: INGN) reported Q4 2021 total revenue of $76.4 million, a 3.3% year-over-year increase. Domestic direct-to-consumer revenue rose 23.3% to $33.0 million, while rental revenue surged 39.4% to $13.0 million. Full-year revenue reached $358.0 million, up 16.1% from 2020. Adjusted EBITDA for Q4 was ($0.5 million) with a net loss of $22.9 million. Supply chain challenges, especially regarding semiconductor availability, are expected to impact operations in 2022. The company anticipates mid-single-digit revenue growth for the year, with negative EBITDA and operating losses projected for Q1 2022.
Inogen, Inc. (NASDAQ: INGN) will release its fourth quarter 2021 financial results after market close on February 24, 2022. A conference call is scheduled for 2:00 PM PT / 5:00 PM ET to discuss the results. Interested parties can listen by calling (877) 841-3961 for domestic and (201) 689-8589 for international callers. A replay will be available starting at 4:00 PM PT on the same day until March 10, 2022. More information is accessible via their Investor Relations website.
Inogen, Inc. (NASDAQ: INGN) announced preliminary Q4 2021 revenue between
Gelesis has appointed
FAQ
What is the current stock price of Inogen (INGN)?
What is the market cap of Inogen (INGN)?
What does Inogen Inc. do?
What is Inogen's flagship product?
How does Inogen sell its products?
Where does Inogen generate most of its revenue?
How many patients use oxygen therapy according to Inogen?
What makes Inogen's products stand out?
What is the mission of Inogen Inc.?
Who inspired the founding of Inogen?
Where can I learn more about Inogen's history?